New fluoroquinolones active against fluoroquinolones-resistant Mycobacterium tuberculosis strains

Tuberculosis

Volumn 93, Issue 4, 2013, Pages 405-411

  Guerrini, Valentina ^a   De Rosa, Maria ^a,b   Pasquini, Serena ^a   Mugnaini, Claudia ^a   Brizzi, Antonella ^a   Cuppone, Anna Maria ^a   Pozzi, Gianni ^a   Corelli, Federico ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antimycobacterial activity; Fluoroquinolone; Fluoroquinolone resistant strain; Synthesis; Tuberculosis

Indexed keywords

1 (TERT BUTYL) 6 FLUORO 7 (4 HYDROXYPHENYL) 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 (TERT BUTYL) 6 FLUORO 7 (4 PYRIDIN 3 YL) 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; IRLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CELL COUNT; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; CELL LINE; CULTURE MEDIA; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GENOTYPE; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84878922890     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2013.02.017     Document Type: Article

References (37)

1. Multidrug and extensively drug resistant TB (M/XDR-TB) Global report on surveillance and response 2010 World Health Organization Geneva, Switzerland Available from: http://whqlibdoc.who.int/publications/2010/9789241599191-eng.pdf
2. H.M. Blumberg, W.J. Burman, R.E. Chaisson, C.L. Daley, S.C. Etkind, L.N. Friedman, P. Fujiwara, M. Grzemska, P.C. Hopewell, M.D. Iseman, R.M. Jasmer, V.R. Koppaka, R.J. Menzies, R.J. O'Brien, R.R. Reves, L.B. Reichman, P.M. Simone, J.R. Starke, A.A. Vernon, and C. Peloquin American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis Am J Respir Crit Care Med 167 2003 603 662
3. WHO Treatment of tuberculosis: guidelines 4th ed. 2010 Available from: http://whqlibdoc.who.int/publications/2010/9789241547833-eng.pdf
4. P.M. Hawkey Mechanisms of quinolone action and microbial response J Antimicrob Chemother 51 Suppl. S1 2003 29 35
5. D.C. Hooper Mechanisms of fluoroquinolone resistance Drug Resist Updat 2 1999 38 55
6. K. Mdluli, and Z. Ma Mycobacterium tuberculosis DNA gyrase as a target for drug discovery Infect Disord Drug Targets 7 2007 159 168
7. H.E. Takiff, L. Salazar, C. Guerrero, W. Philipp, W.M. Huang, B. Kreiswirth, S.T. Cole, W.R. Jacobs Jr., and A. Telenti Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations Antimicrob Agents Chemother 38 1994 773 780
8. A. Aubry, N. Veziris, E. Cambau, C. Truffot-Pernot, V. Jarlier, and L.M. Fisher Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes Antimicrob Agents Chemother 50 2006 104 112
9. N. Veziris, C. Martin, F. Brossier, F. Bonnaud, F. Denis, and A. Aubry Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance Eur J Clin Microbiol Infect Dis 26 2007 423 425
10. S. Matrat, N. Veziris, C. Mayer, V. Jarlier, C. Truffot-Pernot, J. Camuset, E. Bouvet, E. Cambau, and A. Aubry Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones Antimicrob Agents Chemother 50 2006 4170 4173
11. J. Piton, S. Petrella, M. Delarue, G. André-Leroux, V. Jarlier, A. Aubry, and C. Mayer Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase PLoS One 5 2010 e12245 10.1371/journal.pone.0012245
12. A.S. Ginsburg, J.H. Grosset, and W. Bishai Fluoroquinolones, tuberculosis, and resistance Lancet Infect Dis 3 2003 432 442
13. M.R. Pasca, P. Guglierame, F. Arcesi, M. Bellinzoni, E. De Rossi, and G. Riccardi Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis Antimicrob Agents Chemother 48 2004 3175 3178
14. C.M. Oliphant, D. Pharm, and G.M. Green Quinolones: a comprehensive review Clin Pharm 65 2002 455 464
15. V.T. Andriole The quinolones: past, present, and future Clin Infect Dis 41 2005 S113 S119
16. J.M. Domagala, and S.E. Hagen Structure-activity relationships of the quinolone antibacterials in the new millennium: some things change and some do not D.C. Hooper, E. Rubinstein, Quinolone antimicrobial agents 2003 ASM Press Washington, D.C. 3 18 [Chapter 1]
17. L.A. Mitscher, and Z. Ma Structure-activity relationship of quinolones A.R. Ronald, D.E. Low, Fluoroquinolone antibiotics 2003 Birkhäuser Verlag Basel 11 48
18. L.R. Peterson Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity Clin Infect Dis 33 2001 S180 S186
19. P.C. Appelbaum, and P.A. Hunter The fluoroquinolone antibacterials: past, present and future perspectives Int J Antimicrob Agents 16 2000 5 15
20. A. Bryskier, and J. Lowther Fluoroquinolones and tuberculosis Expert Opin Investig Drugs 11 2002 233 258
21. N. Minovski, M. Vracko, and T. Solmaier Quantitative structure-activity relationship study of antitubercular fluoroquinolones Mol Divers 15 2011 417 426
22. Y.-L. Zhao, Y.-L. Chen, J.-Y. Sheu, I.-L. Chen, T.-C. Wang, and C.-C. Tzeng Synthesis and antimycobacterial evaluation of certain fluoroquinolones derivatives Bioorg Med Chem 13 2005 3921 3926
23. T.E. Renau, J.P. Sanchez, J.W. Gage, J.A. Dever, M.A. Shapiro, S.J. Gracheck, and J.M. Domagala Structure-activity relationship of quinolone antibacterial agents against mycobacteria: effect of structural changes at N-1 and C-7 J Med Chem 39 1996 729 735
24. T.E. Renau, J.W. Gage, J.A. Dever, G.E. Roland, E.T. Joannides, M.A. Shapiro, J.P. Sanchez, S.J. Gracheck, J.M. Domagala, M.R. Jacobs, and R.C. Reynolds Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position Antimicrob Agents Chemother 40 1996 2363 2368
25. M. Artico, A. Mai, G. Sbardella, S. Massa, C. Musiu, S. Lostia, F. Demontis, and P. La Colla Nitroquinolones with broad-spectrum antimycobacterial activity in vitro Bioorg Med Chem Lett 9 1999 1651 1656
26. G. Stefancich, M. Artico, F. Corelli, S. Massa, S. Panico, and N. Simonetti 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1H-pyrrol-1-yl)quinoline-3- carboxylic acid, a new fluorinated compound of oxacin family with high broad-spectrum antibacterial activities Farmaco Sci 40 1985 237 243
27. M. Casal, J. Gutierrez, P. Ruiz, and G. Moreno Preliminary study of the in vitro activity of irloxacin against mycobacteria Chemotherapy 41 1995 204 207
28. Gilligan PJ, McGuirk PR, Witty MJ. 7-Heterocyclic-1,4-dihydroquinolones as medical bactericides. Patent: US4636506 A; 1987.
29. Gilligan PJ, Witty MJ, McGuirk PR. Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them. Patent: EP0184384 (A1); 1986.
30. B. Romanowski, T.W. Austin, F.L. Pattison, D. Lawee, D. Portnoy, K.F. Givan, E.L. Li, and K.B. Nguyen Rosoxacin in the therapy of uncomplicated gonorrhea Antimicrob Agents Chemother 25 1984 455 457
31. S. Hedge, and M. Schmidt To market, to market-2007 J.E. Macor, Annual reports in medicinal chemistry 2008 Academic Press San Diego, CA 455 497 [Chapter 25]
32. M. Reuman, S.J. Daum, B. Singh, M.P. Wentland, R.B. Perni, P. Pennock, P.M. Carabateas, M.D. Gruett, M.T. Saindane, P.H. Dorff, S.A. Coughlin, D.M. Sedlock, J.B. Rake, and G.Y. Lesher Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents J Med Chem 38 1995 2531 2540
33. De Rosa M. PhD thesis. University of Siena; 2012.
34. S. Pasquini, L. Botta, T. Semeraro, C. Mugnaini, A. Ligresti, E. Palazzo, S. Maione, V. Di Marzo, and F. Corelli Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo J Med Chem 51 2008 5075 5084
35. J.-Y. Wang, L.-N. Lee, H.-C. Lai, S.-K. Wang, I.-S. Jan, C.-J. Yu, P.-R. Hsueh, and P.-C. Yang Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure J Antimicrob Chemother 59 2007 860 865
36. S. Sethi, J. Mandal, P. Kumar, S. Kumar, S. Meharwal, S.K. Jindal, and M. Sharma Susceptibility testing of Mycobacterium tuberculosis by broth microdilution method: a rapid alternative method Diagn Microbiol Infect Dis 57 2007 447 449
37. R. Jayaram, S. Gaonkar, P. Kaur, B.L. Suresh, B.N. Mahesh, R. Jayashree, V. Nandi, S. Bharat, R.K. Shandil, E. Kantharaj, and V. Balasubramanian Pharmacokinetics-pharmacodynamics of rifampin in a aerosol infection model of tuberculosis Antimicrob Agents Chemother 47 2003 2118 2124